Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | DGKZ | Q13574 | 1/20 | 0.38 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22181485 | 0.87 | PDE10A (0.37) | PDE10ADGKZMBOAT4MCHR1HCRTR1 | |
| SCHEMBL21117240 | 0.82 | HRH1 (0.39) | PDE10ADGKZMCHR1 | |
| SCHEMBL18948948 | 0.81 | MAPK8 (0.42) | MCHR1HCRTR1HCRTR2 | |
| SCHEMBL17356166 | 0.80 | MBOAT4 (0.36) | PDE10ADGKZMBOAT4HCRTR1HCRTR2 | |
| SCHEMBL27929264 | 0.77 | MBOAT4 (0.35) | PDE10ADGKZMBOAT4HCRTR1HCRTR2 | |
| SCHEMBL19121603 | 0.73 | POLB (0.34) | MCHR1 | |
| SCHEMBL18672330 | 0.73 | HTT (0.41) | MCHR1 | |
| SCHEMBL21117063 | 0.72 | HRH1 (0.37) | PDE10ADGKZ | |
| SCHEMBL2563280 | 0.71 | DGKZ (0.34) | DGKZ | |
| SCHEMBL18596915 | 0.71 | TSHR (0.33) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207726-A1 | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207726-A1 | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | RORA, RORC, RORB | PDE10A 2092/4885DGKZ 2878/4885MBOAT4 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.